Health Care [ 9/12 ] | Biotechnology [ 47/73 ]
NASDAQ | Common Stock
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies.
The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases.
It has a license, development, and commercialization agreement with F.
Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43.
Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 25 | -1.12 Increased by +16.42% | -1.03 Decreased by -8.56% |
| Feb 10, 25 | -1.08 Increased by +14.29% | -1.04 Decreased by -3.74% |
| Nov 4, 24 | -1.10 Decreased by -389.47% | -1.18 Increased by +6.78% |
| Aug 8, 24 | 1.22 Increased by +218.45% | -1.05 Increased by +216.19% |
| May 8, 24 | -1.34 Decreased by -50.56% | -1.20 Decreased by -11.67% |
| Feb 15, 24 | -1.26 Decreased by -1.15 K% | -1.22 Decreased by -3.28% |
| Nov 2, 23 | 0.38 Increased by +139.18% | -0.32 Increased by +218.75% |
| Aug 3, 23 | -1.03 Decreased by -17.05% | -1.00 Decreased by -3.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 2.83 M Increased by +5.56 K% | -60.20 M Increased by +16.67% | Decreased by -2.13 K% Increased by +98.53% |
| Dec 31, 24 | 2.12 M Increased by +571.84% | -57.96 M Increased by +14.11% | Decreased by -2.73 K% Increased by +87.22% |
| Sep 30, 24 | 970.00 K Decreased by -98.86% | -59.00 M Decreased by -369.32% | Decreased by -6.08 K% Decreased by -23.66 K% |
| Jun 30, 24 | 132.01 M Increased by +3.18 K% | 66.89 M Increased by +222.51% | Increased by +50.67% Increased by +103.73% |
| Mar 31, 24 | 50.00 K Decreased by -97.69% | -72.24 M Decreased by -54.15% | Decreased by -144.48 K% Decreased by -6.59 K% |
| Dec 31, 23 | 316.00 K Decreased by -99.37% | -67.48 M Decreased by -1.16 K% | Decreased by -21.35 K% Decreased by -168.00 K% |
| Sep 30, 23 | 84.87 M Increased by +5.49 K% | 21.91 M Increased by +147.87% | Increased by +25.81% Increased by +100.86% |
| Jun 30, 23 | 4.02 M Increased by +206.33% | -54.59 M Decreased by -32.37% | Decreased by -1.36 K% Increased by +56.79% |